CD137 stimulation enhances cetuximab-induced natural killer: Dendritic cell priming of antitumor T-cell immunity in patients with head and neck cancer

Clinical Cancer Research

Volumn 23, Issue 3, 2017, Pages 707-716

  Srivastava, Raghvendra M ^a   Trivedi, Sumita ^a   Concha Benavente, Fernando ^a   Gibson, Sandra P ^a   Reeder, Carly ^a   Ferrone, Soldano ^b   Ferris, Robert L ^a,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN PEPTIDE TRANSPORTER 2; CD137 ANTIGEN; CD16 ANTIGEN; CD86 ANTIGEN; CETUXIMAB; FC RECEPTOE IIIA; HLA DR ANTIGEN; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; UNCLASSIFIED DRUG; URELUMAB; CD137 LIGAND; CYTOKINE; FC RECEPTOR; FCGR3A PROTEIN, HUMAN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TNFSF9 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 9;

ADAPTIVE IMMUNITY; ADULT; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PROCESSING MACHINERY; ARTICLE; CANCER INHIBITION; CELL MATURATION; CELL SURVIVAL; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE RELEASE; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; INFORMED CONSENT; INNATE IMMUNITY; LIMIT OF QUANTITATION; MALE; NATURAL KILLER CELL; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; TREATMENT RESPONSE; UPREGULATION; AGONISTS; BIOSYNTHESIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HEAD AND NECK TUMOR; IMMUNOLOGY; LYMPHOCYTE; METABOLISM; PATHOLOGY; RECEPTOR CROSS-TALK; SECRETION (PROCESS); SQUAMOUS CELL CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE;

4-1BB LIGAND; ANTIBODIES, MONOCLONAL; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CETUXIMAB; CYTOKINES; DENDRITIC CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HEAD AND NECK NEOPLASMS; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTES; LYMPHOCYTES, TUMOR-INFILTRATING; POLYMORPHISM, GENETIC; RECEPTOR CROSS-TALK; RECEPTORS, IGG; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 9; UP-REGULATION;

EID: 85012303370     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-0879     Document Type: Article

References (34)

1. Ferris RL.Immunology and immunotherapy of head and neck cancer. J Clin Oncol 2015;33:3293-304.
2. Srivastava RM, Lee SC, Andrade Filho PA, Lord CA, Jie HB, Davidson HC, et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res 2013;19:1858-72.
3. Trivedi S, Concha-Benavente F, Srivastava RM, Jie HB, Gibson SP, Schmitt NC, et al. Immune biomarkers of anti-EGFR monoclonal antibody therapy. Ann Oncol 2015;26:40-7.
4. Lopez-Albaitero A, Lee SC, Morgan S, Grandis JR, Gooding WE, Ferrone S, et al. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother 2009;58:1853-64.
5. Lopez-Albaitero A, Ferris RL. Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer. Arch Otolaryngol Head Neck Surg 2007;133:1277-81.
6. Lee SC, Srivastava RM, Lopez-Albaitero A, Ferrone S, Ferris RL. Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. Immunol Res 2011;50:248-54.
7. Andrade Filho PA, Lopez-Albaitero A, Gooding W, Ferris RL. Novel immunogenic HLA-A∗0201-restricted epidermal growth factor receptor-specific T-cell epitope in head and neck cancer patients. J Immunother 2010;33:83-91.
8. Schuler PJ, Boeckers P, Engers R, Boelke E, Bas M, Greve J, et al. EGFR-specific T cell frequencies correlate with EGFR expression in head and neck squamous cell carcinoma. J Transl Med 2011;9:168.
9. The Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517:576-82.
10. Ferris RL, Whiteside TL, Ferrone S. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res 2006;12:3890-5.
11. Ascierto PA, Kalos M, Schaer DA, Callahan MK, Wolchok JD. Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res 2013;19:1009-20.
12. +regulatory T cells in induced tolerance to experimental autoimmune thyroiditis. Cell Immunol 2003;226:20-9.
13. +T cells specific for self-tumor and non-self-tumor antigens for adoptive T-cell therapy. J Immunother 2014;37:225-36.
14. Zhang X, Voskens CJ, Sallin M, Maniar A, Montes CL, Zhang Y, et al. CD137 promotes proliferation and survival of human B cells. J Immunol 2010;184:787-95.
15. Kohrt HE, Colevas AD, Houot R, Weiskopf K, Goldstein MJ, Lund P, et al. Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest 2014;124:2668-82.
16. Langstein J, Becke FM, Sollner L, Krause G, Brockhoff G, Kreutz M, et al. Comparative analysis of CD137 and LPS effects on monocyte activation, survival, and proliferation. Biochem Biophys Res Commun 2000;273:117-22.
17. Wilcox RA, Chapoval AI, Gorski KS, Otsuji M, Shin T, Flies DB, et al. Cutting edge: expression of functional CD137 receptor by dendritic cells. J Immunol 2002;168:4262-7.
18. +T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J Immunol 2002;169:4882-8.
19. Vinay DS, Kwon BS. 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy. BMB Rep 2014;47:122-9.
20. Houot R, Kohrt H. CD137 stimulation enhances the vaccinal effect of antitumor antibodies. Oncoimmunology 2014;3:e941740.
21. Murillo O, Dubrot J, Palazon A, Arina A, Azpilikueta A, Alfaro C, et al. In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb. Eur J Immunol 2009;39:2424-36.
22. Kuang Y, Weng X, Liu X, Zhu H, Chen Z, Chen H. Effects of 4-1BB signaling on the biological function of murine dendritic cells. Oncol Lett 2012;3:477-81.
23. Jie HB, Gildener-Leapman N, Li J, Srivastava RM, Gibson SP, Whiteside TL, et al. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br J Cancer 2013;109:2629-35.
24. Zhao M, Sano D, Pickering CR, Jasser SA, Henderson YC, Clayman GL, et al. Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res 2011;17:7248-64.
25. Heo DS, Snyderman C, Gollin SM, Pan S, Walker E, Deka R,et al. Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines. Cancer Res 1989;49:5167-75.
26. Lopez-Albaitero A, Mailliard R, Hackman T, Andrade Filho PA, Wang X, Gooding W, et al. Maturation pathways of dendritic cells determine TAP1 and TAP2 levels and cross-presenting function. J Immunother 2009;32:465-73.
27. Srivastava RM, Trivedi S, Concha-Benavente F, Hyun-Bae J, Wang L, Seethala RR, et al. STAT1-Induced HLA Class I upregulation enhances immunogenicity and clinical response to anti-EGFR mAb cetuximab therapy in HNC patients. Cancer Immunol Res 2015;3:936-45.
28. Kroon HM, Li Q, Teitz-Tennenbaum S, Whitfield JR, Noone AM, Chang AE. 4-1BB costimulation of effector T cells for adoptive immunotherapy of cancer: involvement of Bcl gene family members. J Immunother 2007;30:406-16.
29. Macdonald DC, Hotblack A, Akbar S, Britton G, Collins MK, Rosenberg WC. 4-1BB ligand activates bystander dendritic cells to enhance immunization in trans. J Immunol 2014;193:5056-64.
30. Lucido CT, Vermeer PD, Wieking BG, Vermeer DW, Lee JH. CD137 enhancement of HPV positive head and neck squamous cell carcinoma tumor clearance. Vaccines 2014;2:841-53.
31. Srivastava RM, Savithri B, Khar A. Activating and inhibitory receptors and their role in natural killer cell function. Indian J Biochem Biophys 2003;40:291-9.
32. Futagawa T, Akiba H, Kodama T, Takeda K, Hosoda Y, Yagita H, et al. Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int Immunol 2002;14:275-86.
33. Chester C, Marabelle A, Houot R, Kohrt HE. Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors. Curr Opin Immunol 2015;33C:1-8.
34. Ito F, Li Q, Shreiner AB, Okuyama R, Jure-Kunkel MN, Teitz-Tennenbaum S, et al. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines. Cancer Res 2004;64:8411-9.